Skip to main content

Table 3 ME/CFS symptom characteristics

From: The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients

Age of diagnosis (years [mean ± SEM])

29.6 ± 3.05

Disease duration (years [mean ± SEM])

14.93 ± 3.17

Infectious onset, n(%)

13 (86.7%)

Cognitive difficulties

 Yes

15 (100%)

 No

0 (0%)

Pain

 Yes

15 (100%)

 No

0 (0%)

Sleep disturbances

 Yes

15 (100%)

 No

0 (0%)

Sensory disturbances

 Yes

15 (100%)

 No

0 (0%)

Immune disturbances

 Yes

14 (93.3%)

 No

1 (6.7%)

Gastrointestinal disturbances

 Yes

14 (93.3%)

 No

1 (6.7%)

Cardiovascular disturbances

 Yes

15 (100%)

 No

0 (0%)

Respiratory disturbances

 Yes

8 (53.3%)

 No

7 (46.7%)

Thermostatic instability

 Yes

11 (73.3%)

 No

4 (26.7%)

Urinary disturbances

 Yes

5 (33.3%)

 No

10 (66.7%)

  1. ME Myalgic encephalomyelitis, CFS chronic fatigue syndrome, SEM standard error of mean, n number